Study of HRS-7172 for advanced solid tumors with RAS mutations
Part of Cancer clinical trials.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your cancer must have a RAS mutation or amplification (a change in the RAS gene).
- You need to have at least one tumor that can be measured on scans.
- You must be able to do daily activities with little or no help (ECOG score 0 or 1).
- Your organs must be working well (like kidneys, liver, and blood).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug, HRS-4642, combined with other cancer treatments for people with advanced solid tumors. It looks at how well the combination works and if it is safe for you.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This trial tests a new drug called HRS-6719 for people with advanced or metastatic solid tumors that have progressed after standard treatments or for which no standard treatment exists. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Hear when a new Advanced Solid Tumors Harboring RAS Mutations or Amplifications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.